Biomarkers of inflammation, growth factor, and coagulation activation in patients with sickle cell disease

Clinical and Applied Thrombosis/Hemostasis

Volumn 18, Issue 2, 2012, Pages 195-200

  Qari, M H ^a   Dier, U ^b   Mousa, S A ^b  

^a KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^b ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

biomarkers; chemokines; cytokines; growth factors; hypercoagulation; inflammation; neovascularization; painful crisis; sickle cell; steady state; vaso occlusive crisis

Indexed keywords

BIOLOGICAL MARKER; CHEMOKINE; CYTOKINE; FIBROBLAST GROWTH FACTOR 2; GAMMA INTERFERON; GROWTH FACTOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1 ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; SCATTER FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADULT; ARTICLE; BLOOD CLOTTING DISORDER; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; INFLAMMATION; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SICKLE CELL ANEMIA; STEADY STATE; THROMBOSIS;

ACUTE PAIN; ADULT; ANEMIA, SICKLE CELL; ARTERIAL OCCLUSIVE DISEASES; BIOLOGICAL MARKERS; BLOOD COAGULATION; CYTOKINES; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOLYSIS; HUMANS; INFLAMMATION; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; PLATELET ACTIVATION; SAUDI ARABIA; THROMBOPHILIA; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84858425678     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029611420992     Document Type: Article

References (20)

1. Qari MH, Aljaouni SK, Alardawi MS, et al. Reduction of painful vaso-occlusive crisis of sickle cell anemia by tinzaparin in a double-blind randomized trial. Thromb Haemost. 2007 ; 98 (2). 392-396 (Pubitemid 47250243)
2. Aslan M, Freeman BA.. Redox-dependent impairment of vascular function in sickle cell disease. Free Radic Biol Med. 2007 ; 43 (11). 1469-1483 (Pubitemid 47615401)
3. Hebbel RP, Osarogiagbon R, Kaul D.. The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy. Microcirculation. 2004 ; 11 (2). 129-151 (Pubitemid 39619075)
4. Mehta SR, Afenyi-Annan A, Byrns PJ, Lottenberg R.. Opportunities to improve outcomes in sickle cell disease. Am Fam Physician. 2006 ; 74 (2). 303-310
5. Hebbel RP, Boogaerts MA, Eaton JW, Steinberg MH.. Erythrocyte adherence to endothelium in sickle cell anemia: a possible determinant of disease severity. N Engl J Med. 1980 ; 302 (18). 992-995 (Pubitemid 10125408)
6. Grigg AP.. Granulocyte colony-stimulating factor-induced sickle cell crisis and multiorgan dysfunction in a patient with compound heterozygous sickle cell/β+ thalassemia. Blood. 2001 ; 97 (12). 3998-3999
7. De Franceschi L, Cappellini MD, Olivieri O.. Thrombosis and sickle cell disease. Semin Thromb Hemost. 2011 ; 37 (3). 226-236
8. Ataga KI, Key NS.. Hypercoagulability in sickle cell disease: new approaches to an old problem. Hematology Am Soc Hematol Educ Program. 2007 ;: 91-96
9. Inwald DP, Kirkham FJ, Peters MJ, Lane R, Wade A, Evans JP, Klein NJ.. Platelet and leukocyte activation in childhood sickle cell disease: association with nocturnal hypoxemia. Br J Hematol. 2000 ; 111 (2). 474-481 (Pubitemid 32009339)
10. Blann AD, Mohan JS, Bareford D, Lip GY.. Soluble P-selectin and vascular endothelial growth factor in steady state sickle cell disease: relationship to genotype. J Thromb Thrombolysis. 2008 ; 25 (2). 185-189
11. Tomer A, Harker LA, Kasey S, Eckman JR.. Thrombogenesis in sickle cell disease. J Lab Clin Med. 2001 ; 137 (6). 398-407 (Pubitemid 32473618)
12. Key NS, Slungaard A, Dandelet L, et al. Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease. Blood. 1998 ; 91 (11). 4216-4223 (Pubitemid 28261985)
13. Ataga KI, Moore CG, Hillery CA, et al. Coagulation activation and inflammation in sickle cell disease-associated pulmonary hypertension. Haematologica. 2008 ; 93 (1). 20-26 (Pubitemid 351156147)
14. Etienne-Julan M, Belloy MS, Decastel M, Dougaparsad S, Ravion S, Hardy-Dessources MD.. Childhood sickle cell crises: clinical severity, inflammatory markers and the role of interleukin-8. Haematologica. 2004 ; 89 (7). 863-864 (Pubitemid 38981348)
15. Ballas SK.. Current issues in sickle cell pain and its management. Hematology Am Soc Hematol Educ Program. 2007 ;: 97-105
16. Frenette PS, Atweh GF.. Sickle cell disease: old discoveries, new concepts, and future promise. J Clin Invest. 2007 ; 117 (4). 850-858 (Pubitemid 46556737)
17. Schultz JC.. Comparison of radial immunodiffusion and alkaline cellulose acetate electrophoresis for quantitating elevated levels of fetal hemoglobin (HbF): application to evaluating patients with sickle cell disease treated with hydroxyurea. J Clin Lab Anal. 1999 ; 13 (2). 82-89 (Pubitemid 29104629)
18. Mousa SA, Johansen K.. Pharmacodynamic effects of low molecular weight heparin in obese subjects following subcutaneous administration of 75 IU/kg on plasma tissue factor pathway inhibitor and nitric oxide. Int Angiol. 2005 ; 24 (1). 40-42 (Pubitemid 43933047)
19. Emokpae MA, Uadia PO, Gadzama AA.. Correlation of oxidative stress and inflammatory markers with the severity of sickle cell nephropathy. Ann Afr Med. 2010 ; 9 (3). 141-146
20. Mousa SA.. Elevation of plasma von Willebrand factor and tumor necrosis factor-a in obese subjects and their reduction by the low molecular weight heparin tinzaparin. Int. Angiol. 2005 ; 24 (3). 278-281 (Pubitemid 41582337)